Milken Institute59 min
Universities Step Up Their Role in Regional Economic Development
Ross DeVol, Ronald Daniels, Fred Farina, Bahija Jallal, Deval Patrick, Ross Duvall, Ron Daniels
Panel
Regional Innovation Ecosystem Dynamics:
- Innovation clusters (e.g., Silicon Valley, Research Triangle) rely on the spatial proximity of universities, which generate and convey knowledge more efficiently than dispersed entities.
- The "regional innovation life cycle" identifies universities as the primary catalyst for commercialization, entrepreneurship, and industry clustering.
- Geographic contiguity of assets (industry, academia, capital) is a critical determinant of cluster success, which is currently lacking in many regions despite high asset availability.
State Performance and Rankings:
- Massachusetts has ranked #1 in the Milken Institute's State Technology and Science Index every year since 2002.
- Maryland ranked #2 since 2008; California ranked #3.
- Rankings adjust for economy size and measure R&D assets (NIH funding, academic/industry R&D) and human capital commercialization capacity.
Institutional Case Studies and Challenges:
- Johns Hopkins University:
- Inherited a cultural barrier where "publishing was noble, but patenting was not," despite 35 years as the top NIH funding recipient.
- Licensing revenue was ~$18M annually compared to ~$150M at Columbia, highlighting a commercialization gap.
- Leadership shifted the narrative from revenue generation to societal impact, encouraging faculty to see commercialization as part of their responsibility.
- Current Obstacle: Key assets (industry, research) are not geographically contiguous (e.g., MedImmune is 45 minutes away), requiring deliberate intervention to foster a cluster.
- Initiatives: Launched entrepreneurship minors (30%+ of 5,000 undergrads), faculty boot camps, and a joint PhD program with MedImmune/AstraZeneca allowing students to work in industry for one year.
- Caltech:
- Measures success by the transition of lab research to societal products (drugs, devices) rather than direct revenue.
- Competitively hired an Entrepreneur-in-Residence (EIR) for 1–2 years to guide faculty in de-risking technologies and creating business cases.
- Focuses on graduate-level entrepreneurship training, leveraging the fact that these students possess 10+ years of technical experience requiring commercialization tools.
- Johns Hopkins University:
Government and Policy Interventions:
- Massachusetts Life Sciences Initiative (2007–2008):
- State invested $1B over 10 years to catalyze growth during the Great Recession.
- Leverage: Spent ~$500M to leverage $1.8B in private investment and create thousands of jobs.
- Strategy: Addressed "valley of death" funding gaps, provided infrastructure (e.g., sewage for Genzyme in Framingham), and enforced cross-institutional collaboration.
- Inclusivity: Directed investment toward "gateway cities" (e.g., Framingham, Pittsfield) rather than just Cambridge to displace manufacturing and include non-PhD workforce development.
- Federal Role:
- Government funding (NIH) is the foundational "goose that lays the golden eggs"; a 20% real-term budget contraction is cited as a critical threat.
- Panelists propose federal matching funds (e.g., 10–20% of grants set aside for commercialization follow-on) to bridge the gap between basic research and venture capital.
- Risk Management:
- Governments must tolerate higher failure rates to foster innovation, contrasting with standard political risk aversion.
- Public funds should act as catalysts/gap-fillers, not substitutes for private capital, with strict clawbacks if job creation targets are missed.
- Massachusetts Life Sciences Initiative (2007–2008):
Industry Perspectives and Metrics:
- MedImmune/AstraZeneca (Bahija Jalal):
- Collaboration criteria: (1) Strength of science, (2) Cultural alignment and mutual respect, (3) Measurable deliverables beyond "talk."
- Emphasizes that industry and academia must co-exist with "blue sky" research, which companies cannot fund but is essential for long-term discovery.
- Commercialization Efficiency:
- From 1991–2004, $800B in US university federal funding generated 320,000 invention disclosures, 70,000 patents, 37,000 active licenses, and 9,000 startups.
- Failure Rates: Only ~1 in 100 pharma compounds reaches approval; ~1 in 10 venture investments are significant hits.
- MedImmune/AstraZeneca (Bahija Jalal):
Cultural and Educational Shifts:
- Faculty Tenure: A shift is occurring to recognize patents as a legitimate form of creative enterprise alongside publications, though implementation varies by school.
- Student Mindset: "Blue-sky" research and entrepreneurship are no longer mutually exclusive; students increasingly seek market-ready skills without abandoning their core majors.
- K-12 Deficit: A "crisis" in US K-12 numeracy and literacy is identified as a "glass ceiling" threatening the future human capital pipeline for innovation clusters.
Forward-Looking Recommendations:
- One-Page Summary of Key Proposals:
- Ron Daniels: Align public leadership with a coherent, long-term (K-12 to commercialization) strategy; increase funding to bridge the "valley of death."
- Fred Farina: Increase federal investment in commercialization follow-on funding; maintain a protected sector for blue-sky research.
- Bahija Jalal: Prioritize deep collaboration while preserving blue-sky research capabilities.
- Deval Patrick: Governments must model collaboration, ignore short-term election cycles (adopt 10-year horizons), and use "honest broker" funds to force cross-institutional partnerships.
- One-Page Summary of Key Proposals: